Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19983074 | 0.85 | KMT2A (0.40) | RAB9ACTSKLMNAPOLBGAA | |
| SCHEMBL22460583 | 0.73 | ALDH1A1 (0.41) | CTSKCTSS | |
| SCHEMBL3126895 | 0.73 | ATR (0.43) | RAB9AMIFLMNAPOLBTRPA1 | |
| SCHEMBL7008829 | 0.73 | CYP17A1 (0.44) | LMNAPOLBAAK1CYP17A1 | |
| SCHEMBL16319966 | 0.70 | CES2 (0.55) | CES2CES1 | |
| SCHEMBL30739735 | 0.70 | CYP17A1 (0.44) | LMNAPOLBCYP17A1 | |
| SCHEMBL19330781 | 0.70 | ATR (0.56) | CES2CES1LMNAPOLBCYP17A1 | |
| SCHEMBL12557269 | 0.69 | RAB9A (0.45) | RAB9ACTSKLMNAPOLBGAA | |
| SCHEMBL7081259 | 0.69 | NAMPT (0.47) | RAB9ACES2CES1LMNAGAA | |
| SCHEMBL19983031 | 0.69 | SCN9A (0.40) | RAB9ACTSKAAK1GAACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2018053353-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053908-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | RAB9A 4148/4885CTSK 379/4885CES2 1035/4885 |
| US-11325884-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | RAB9A 4148/4885CTSK 379/4885CES2 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.